Effects of cytochrome P450 inducers on 17alpha-ethinyloestradiol (EE2) conjugation by primary human hepatocytes.

AIMS Our objective was to elucidate further the underlying mechanism responsible for therapeutic failures observed with concomitant administration of the oral contraceptive 17alpha-ethinyloestradiol (EE2 ) and rifampicin. METHODS We investigated both oxidative and direct conjugative [3H]-EE2 metabolism by human liver S9 fraction and the effect of known enzyme-inducing drugs using a human hepatocyte induction model in vitro. RESULTS Cofactor dependent [3H]-EE2 metabolism by human liver S9 fraction produced 2-hydroxy-[3H]-EE2, 2-methoxy-[3H]-EE2, and direct [3H]-EE2 sulphate and glucuronide conjugates. Only two detectable metabolites of [3H]-EE2 were produced by the S9 fraction in the presence of all cofactors: [3H]-EE2-3-sulphate (75.7+/-7.6% s. d.) and 2-methoxy-3H-EE2 (2.6%+/-0.5% s.d.). Human hepatocytes extensively metabolized [3H]-EE2 to its glucuronide and sulphate conjugates. Small amounts of a 2-methoxy-[3H]-EE2 3-conjugate, < or = 10%, was observed but no. 2-hydroxy-[3H]-EE2 was detected. An unexpected finding in our study was increased [3H]-EE2-3-sulphate production (1.5-3.3 fold, n=3 donor livers) by hepatocytes pretreated with rifampicin compared to control hepatocytes. No statistically significant increase in [3H]-EE2-3-sulphation was observed in hepatocytes pretreated with 3-methylcholanthrene, phenobarbitone, dexamethasone, or omeprazole over nontreated hepatocytes. To our knowledge, this is the first observation of sulphotransferase induction by rifampicin in human hepatocytes in vitro resulting in increased [3H]-EE2 sulphation. CONCLUSIONS Our data indicate that the major EE2 metabolic products formed by human hepatocytes in vitro are direct EE2 conjugates with EE2 oxidation representing minor pathways. Further studies are required to establish the mechanism of sulphotransferase induction and the clinical relevance of our findings.

[1]  F. Guengerich.  Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. , 1988, Molecular pharmacology.

[2]  B. D. Kulkarni,et al.  A preliminary report on urinary excretion pattern and method of isolation of 14C-ethynylestradiol metabolites in women , 1970 .

[3]  J. Weber,et al.  Interaction between oral contraceptives and griseofulvin. , 1984, British medical journal.

[4]  E. Perucca,et al.  Induction of Ethinylestradiol and Levonorgestrel Metabolism by Oxcarbazepine in Healthy Women , 1999, Epilepsia.

[5]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[6]  J. Maggs,et al.  A comparative study of biliary and urinary 2-hydroxylated metabolites of [6,7-3H]17 alpha-ethynylestradiol in women. , 1985, Contraception.

[7]  A. Breckenridge,et al.  Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. , 1988, British journal of clinical pharmacology.

[8]  A. Breckenridge,et al.  Clinical Pharmacokinetics of Oral Contraceptive Steroids , 1983, Clinical pharmacokinetics.

[9]  J. Thénot,et al.  Toxic agents resulting from the oxidative metabolism of steroid hormones and drugs. , 1978, Journal of toxicology and environmental health.

[10]  C. Wolf,et al.  Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 alpha-ethinyloestradiol. Relative activities of rat and human liver enzymes. , 1990, The Biochemical journal.

[11]  H. Bolt,et al.  Irreversible protein binding of metabolites of ethynylestradiol in vivo and in vitro. , 1973, Steroids.

[12]  R. Mayer,et al.  Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. , 1985, Biochemical pharmacology.

[13]  S. Imaoka,et al.  Purification and characterization of liver microsomal cytochrome P-450 from untreated male rats. , 1987, Biochimica et biophysica acta.

[14]  Collins,et al.  Similarity of metabolism for CAI (NSC 609974) in human liver tissue in vitro and in humans in vivo , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  C. Flexner,et al.  The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive , 1999, Clinical pharmacology and therapeutics.

[16]  Albert P. Li,et al.  Isolation and culturing of hepatocytes from human livers , 1992 .

[17]  A. Li,et al.  Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  A. Li,et al.  Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. , 1997, Chemico-biological interactions.

[19]  C. Falany,et al.  Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  A. Temellini,et al.  Interindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver. , 1991, British journal of clinical pharmacology.

[21]  G. Stramentinoli,et al.  Influence of S-adenosyl-L-methionine on irreversible binding of ethynylestradiol to rat liver microsomes, and its implication in bile secretion. , 1979, Biochemical pharmacology.

[22]  R. Brodell,et al.  Oral contraceptive failure rates and oral antibiotics. , 1997, Journal of the American Academy of Dermatology.

[23]  K. Fotherby,et al.  Metabolism of ethynyloestradiol in man. , 1972, The Journal of endocrinology.

[24]  N. Kitteringham,et al.  A comparative study of the formation of chemically reactive drug metabolites by human liver microsomes. , 1988, British journal of clinical pharmacology.

[25]  A. Breckenridge,et al.  The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. , 1980, Contraception.

[26]  H. Bolt,et al.  Metabolism of 17 alpha-ethinylestradiol by human liver microsomes in vitro: aromatic hydroxylation and irreversible protein binding of metabolites. , 1974, The Journal of clinical endocrinology and metabolism.

[27]  M. P. Arlotto,et al.  Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. , 1987, Archives of biochemistry and biophysics.

[28]  K. Fotherby,et al.  Metabolism of 4-14C–Ethynyl Oestradiol in Women , 1969, Nature.

[29]  D. Back,et al.  Sulphation and glucuronidation of ethinyloestradiol in human liver in vitro. , 1988, Journal of steroid biochemistry.

[30]  B. K. Park,et al.  The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. , 1987, British journal of clinical pharmacology.

[31]  C. Falany,et al.  Steroid sulfation by expressed human cytosolic sulfotransferases , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  P. McDaniel,et al.  Oral Contraceptives and Griseofulvin Interaction , 1986 .

[33]  K. Williams,et al.  Metabolism of radioactive 17α-ethynylestradiol by women , 1970 .

[34]  A. Meli,et al.  Fate of ingested radiolabeled ethynylestradiol and its 3-cyclopentyl ether in patients with bile fistulas. , 1969, The Journal of clinical endocrinology and metabolism.

[35]  R. Pichlmayr,et al.  Drug metabolism in hepatocyte sandwich cultures of rats and humans. , 1997, Biochemical pharmacology.

[36]  D. Back,et al.  Interindividual variation in the metabolism of ethynylestradiol. , 1989, Pharmacology & therapeutics.

[37]  A. Breckenridge,et al.  The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. , 1980, Contraception.

[38]  D. Back,et al.  Pharmacokinetic Drug Interactions with Oral Contraceptives , 1990, Clinical pharmacokinetics.

[39]  D. Back,et al.  The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. , 1990, British journal of clinical pharmacology.

[40]  H. Bolt,et al.  Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. , 1977, Acta endocrinologica.

[41]  G. Shenfield,et al.  Clinical Pharmacokinetics of Contraceptive Steroids An Update , 1991, Clinical pharmacokinetics.

[42]  J. Goldzieher,et al.  Chromatographic patterns of urinary ethynyl estrogen metabolites in various populations , 1980, Steroids.

[43]  T. Shimada,et al.  Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[44]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[45]  A. Breckenridge,et al.  The biliary and urinary metabolites of [3H]17α-ethynylestradiol in women , 1983 .

[46]  M. Williams,et al.  The urinary metabolites of 17α-ethynylestradiol-9α,11-3H in women chromatographic profiling and identification of ethynyl and non-ethynyl compounds , 1975, Steroids.